731 related articles for article (PubMed ID: 18054386)
1. Studies on the haemolytic activity of circulating C1q-C3/C4 complexes.
Wouters D; Brouwer MC; Daha MR; Hack CE
Mol Immunol; 2008 Apr; 45(7):1893-9. PubMed ID: 18054386
[TBL] [Abstract][Full Text] [Related]
2. Complexes between C1q and C3 or C4: novel and specific markers for classical complement pathway activation.
Wouters D; Wiessenberg HD; Hart M; Bruins P; Voskuyl A; Daha MR; Hack CE
J Immunol Methods; 2005 Mar; 298(1-2):35-45. PubMed ID: 15847795
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of classical complement pathway activation in rheumatoid arthritis: measurement of C1q-C4 complexes as novel activation products.
Wouters D; Voskuyl AE; Molenaar ET; Dijkmans BA; Hack CE
Arthritis Rheum; 2006 Apr; 54(4):1143-50. PubMed ID: 16572449
[TBL] [Abstract][Full Text] [Related]
4. Prevention of immune precipitation by purified classical pathway complement components.
Naama JK; Hamilton AO; Yeung-Laiwah AC; Whaley K
Clin Exp Immunol; 1984 Nov; 58(2):486-92. PubMed ID: 6333948
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
[TBL] [Abstract][Full Text] [Related]
6. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
Brown EJ; Ramsey J; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
[TBL] [Abstract][Full Text] [Related]
7. Human astrovirus coat protein binds C1q and MBL and inhibits the classical and lectin pathways of complement activation.
Hair PS; Gronemus JQ; Crawford KB; Salvi VP; Cunnion KM; Thielens NM; Arlaud GJ; Rawal N; Krishna NK
Mol Immunol; 2010 Jan; 47(4):792-8. PubMed ID: 19896716
[TBL] [Abstract][Full Text] [Related]
8. Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition.
Ziccardi RJ
J Immunol; 1986 May; 136(9):3378-83. PubMed ID: 3485688
[TBL] [Abstract][Full Text] [Related]
9. Antibody-independent activation of C1. II. Evidence for two classes of nonimmune activators of the classical pathway of complement.
Peitsch MC; Kovacsovics TJ; Tschopp J; Isliker H
J Immunol; 1987 Mar; 138(6):1871-6. PubMed ID: 3029223
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
Kievits F; Kijlstra A
Immunology; 1985 Mar; 54(3):449-56. PubMed ID: 3844370
[TBL] [Abstract][Full Text] [Related]
11. Anti-C1q column: ligand specific purification of immune complexes from human serum or plasma. Analysis of the interaction between C1q and immune complexes.
Kilgallon W; Amlot PL; Williams BD
Clin Exp Immunol; 1982 Jun; 48(3):705-14. PubMed ID: 6811171
[TBL] [Abstract][Full Text] [Related]
12. Complement activation and impaired capacity to solubilize immune complexes or to prevent their formation in essential mixed cryoglobulinemia.
Corvetta A; Spaeth PJ; Ghirelli PA; Orecchioni F; Buetler R; Montroni M; Nydegger UE
Diagn Immunol; 1983; 1(4):315-23. PubMed ID: 6333960
[TBL] [Abstract][Full Text] [Related]
13. Depressed classical complement pathway activities in chronic lymphocytic leukaemia.
Füst G; Czink E; Minh D; Miszlay Z; Varga L; Hollán SR
Clin Exp Immunol; 1985 Jun; 60(3):489-95. PubMed ID: 4017286
[TBL] [Abstract][Full Text] [Related]
14. Regulation of immune complex-mediated complement activation by autoantibodies (F-42) isolated from sera of patients with systemic lupus erythematosus.
Daha MR; Hazevoet HM; Vanes LA
Clin Exp Immunol; 1983 Sep; 53(3):541-6. PubMed ID: 6604604
[TBL] [Abstract][Full Text] [Related]
15. Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway.
Makinde VA; Senaldi G; Jawad AS; Berry H; Vergani D
Ann Rheum Dis; 1989 Apr; 48(4):302-6. PubMed ID: 2785367
[TBL] [Abstract][Full Text] [Related]
16. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
Kozlov LV; Shibanova ED; Zinchenko AA
Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of immune precipitation by complement.
Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
[TBL] [Abstract][Full Text] [Related]
18. C1 subcomponent complexes: basic and clinical aspects.
Laurell AB; Sjöholm AG
Behring Inst Mitt; 1993 Dec; (93):292-8. PubMed ID: 8172579
[TBL] [Abstract][Full Text] [Related]
19. Relative importance of C4 binding protein in the modulation of the classical pathway C3 convertase in patients with systemic lupus erythematosus.
Daha MR; Hazevoet HM; Hermans J; van Es LA; Cats A
Clin Exp Immunol; 1983 Oct; 54(1):248-52. PubMed ID: 6604610
[TBL] [Abstract][Full Text] [Related]
20. C3, C4, and the terminal complement complex differ from C1q by binding predominantly to the antigenic part of solid phase immune complexes.
Garred P; Michaelsen TE; Aase A; Mollnes TE
J Immunol; 1990 Jan; 144(1):198-203. PubMed ID: 2295791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
